E0259 - Home Care In-Use Evaluation of Intermittent Colonic Exoperistalsis (ICE) Device to Treat Chronic Functional Constipation in the General Population

Immaculada Herrero-Fresneda, PhD
MOWOOT, USMIMA S.L., Esplugues de Llobregat, Catalonia, Spain

Introduction: Up to 24% of the general population is diagnosticated of chronic constipation, leading to negative clinical and social consequences for patients and additional costs for the health care systems.

Intermittent colonic exoperistalsis (ICE) treatment administered with the MOWOOT medical device, is a non-invasive, non-drug solution for the treatment of chronic constipation. It has been developed to facilitate natural bowel movements and reduce the side effects of laxatives, enemas, or other invasive approaches. The ICE medical device has been proven in a multicentric clinical trial to be safe and effective in constipation from either neurogenic or idiopathic etiology (McClurg et al., CTG 2020).

Methods: Patients with chronic functional constipation, with or without previous diagnosis of slow bowel transit were recruited in 4 hospitals in Germany. The treatment consisted in using the ICE device for 15 to 30min daily, at home. In-use-evaluation was performed through anonymous, structured feedbacks collected at baseline (F1) and after some time under ICE treatment (F2). Satisfaction, tolerability, and usability were valued by patients from 1 (very high) to 6 (very low).

Results: Data resulted from n=18 patients (17 female, 1 male), from 18 to 75 yr (average age 49,06 (18,52) yr). Most of patients (66.67%) have a previous diagnosis of slow bowel transit. The mean time of ICE treatment at F2-feedback collection was 6,33(5,18) months (min 0,5; max 16). No one reported any serious adverse event. Six patients described occasional low to moderate abdominal pain, which did not affect the treatment compliance.
There was a significant improvement in bowel function (Table) toghether with a reduction in laxative use (6 patients stopped and 5 reduced oral laxatives, 61.1%, Chi² P= 0.0018). The satisfaction with bowel function and management increased in average by 40.6% after the ICE treatment. Tolerability and usability of the ICE device were rated as high or very high by 87.5% and 88.2% of patients, respectively.

Discussion: The high number of satisfied patients relates with the clinically significant amelioration in their bowel function. Especially concerning the reduction by ~1h in time spent per evacuation. This structured feedback in the out-patient sector demonstrates the medical benefit of ICE in constipated patients with or without slow bowel transit. Therefore, the ICE device has the potential to substitute more conservative approaches in bowel management strategies of the general population.




Disclosures:


Immaculada Herrero-Fresneda, PhD. E0259 - Home Care In-Use Evaluation of Intermittent Colonic Exoperistalsis (ICE) Device to Treat Chronic Functional Constipation in the General Population, ACG 2022 Annual Scientific Meeting Abstracts. Charlotte, NC: American College of Gastroenterology.